NCT05283486View on ClinicalTrials.gov

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 7, 2023

Study Completion Date

June 7, 2023

Conditions
SarcopeniaFrailtyAging
Interventions
DRUG

MYMD-1 600MG

Cohort 1: 600mg drug

DRUG

MYMD-1 750mg

Cohort 2: 750mg drug

DRUG

MYMD-1 900mg

Cohort 3: 900mg drug

DRUG

MYMD-1 1050mg

Cohort 4: 1050mg drug

DRUG

placebo 600mg

Cohort 1: 600mg placebo

DRUG

placebo 750mg

Cohort 2: 750mg placebo

DRUG

placebo 900mg

Cohort 3: 900mg placebo

DRUG

placebo 1050mg

Cohort 4: 1050mg placebo

Trial Locations (3)

21224

Johns Hopkins Bayview Medical Center, Baltimore

33606

Clinical Research of West Florida, Tampa

33765

Clinical Research of West Florida, Inc, Clearwater

All Listed Sponsors
lead

TNF Pharmaceuticals, Inc.

INDUSTRY